Cargando…
Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
OBJECTIVE: This study aimed to determine the efficacy, effectiveness, and cost-effectiveness of inactivated COVID-19 vaccines (CoronaVac and BBIBP-CorV) in China using existing international clinical trials and real-world evidence. METHODS: Through a search of PubMed, Embase, Web of Science, and CNK...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343737/ https://www.ncbi.nlm.nih.gov/pubmed/35928479 http://dx.doi.org/10.3389/fpubh.2022.917732 |
_version_ | 1784761055724961792 |
---|---|
author | Fu, Yaqun Zhao, Jingyu Wei, Xia Han, Peien Yang, Li Ren, Tao Zhan, Siyan Li, Liming |
author_facet | Fu, Yaqun Zhao, Jingyu Wei, Xia Han, Peien Yang, Li Ren, Tao Zhan, Siyan Li, Liming |
author_sort | Fu, Yaqun |
collection | PubMed |
description | OBJECTIVE: This study aimed to determine the efficacy, effectiveness, and cost-effectiveness of inactivated COVID-19 vaccines (CoronaVac and BBIBP-CorV) in China using existing international clinical trials and real-world evidence. METHODS: Through a search of PubMed, Embase, Web of Science, and CNKI, studies investigating the effectiveness of inactivated COVID-19 vaccines were identified, and a meta-analysis was undertaken to synthesize the vaccine efficacy and effectiveness data. Moreover, a decision-analytic model was developed to estimate the cost-effectiveness of inactivated vaccines for combating the COVID-19 pandemic in the Chinese context from a societal perspective. Results of the meta-analysis, along with cost data from official websites and works of literature were used to populate the model. Sensitivity analysis was performed to test the robustness of the model results. RESULTS: A total of 24 studies were included in the meta-analysis. In comparison to no immunization, the effectiveness of inactivated vaccine against COVID-19 infection, hospitalization, ICU admission and death were 65.18% (95% CI 62.62, 67.75), 79.10% (95% CI 71.69, 86.51), 90.46% (95% CI 89.42, 91.50), and 86.69% (95% CI 85.68, 87.70); and the efficacy against COVID-19 infection and hospitalization were 70.56% (95% CI 57.87, 83.24) and 100% (95% CI 61.72, 100). Inactivated vaccine vaccination prevented more infections, hospitalizations, ICU admissions, and deaths with lower total costs, thus was cost-saving from a societal perspective in China. Base-case analysis results were robust in the one-way sensitivity analysis, and the percentage of ICU admission or death and direct medical cost ranked the top influential factors in our models. In the probabilistic sensitivity analysis, vaccination had a 100% probability of being cost-effective. CONCLUSION: Inactivated vaccine is effective in preventing COVID-19 infection, hospitalization, ICU admission and avoiding COVID-19 related death, and COVID-19 vaccination program is cost-saving from societal perspective in China. |
format | Online Article Text |
id | pubmed-9343737 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93437372022-08-03 Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies Fu, Yaqun Zhao, Jingyu Wei, Xia Han, Peien Yang, Li Ren, Tao Zhan, Siyan Li, Liming Front Public Health Public Health OBJECTIVE: This study aimed to determine the efficacy, effectiveness, and cost-effectiveness of inactivated COVID-19 vaccines (CoronaVac and BBIBP-CorV) in China using existing international clinical trials and real-world evidence. METHODS: Through a search of PubMed, Embase, Web of Science, and CNKI, studies investigating the effectiveness of inactivated COVID-19 vaccines were identified, and a meta-analysis was undertaken to synthesize the vaccine efficacy and effectiveness data. Moreover, a decision-analytic model was developed to estimate the cost-effectiveness of inactivated vaccines for combating the COVID-19 pandemic in the Chinese context from a societal perspective. Results of the meta-analysis, along with cost data from official websites and works of literature were used to populate the model. Sensitivity analysis was performed to test the robustness of the model results. RESULTS: A total of 24 studies were included in the meta-analysis. In comparison to no immunization, the effectiveness of inactivated vaccine against COVID-19 infection, hospitalization, ICU admission and death were 65.18% (95% CI 62.62, 67.75), 79.10% (95% CI 71.69, 86.51), 90.46% (95% CI 89.42, 91.50), and 86.69% (95% CI 85.68, 87.70); and the efficacy against COVID-19 infection and hospitalization were 70.56% (95% CI 57.87, 83.24) and 100% (95% CI 61.72, 100). Inactivated vaccine vaccination prevented more infections, hospitalizations, ICU admissions, and deaths with lower total costs, thus was cost-saving from a societal perspective in China. Base-case analysis results were robust in the one-way sensitivity analysis, and the percentage of ICU admission or death and direct medical cost ranked the top influential factors in our models. In the probabilistic sensitivity analysis, vaccination had a 100% probability of being cost-effective. CONCLUSION: Inactivated vaccine is effective in preventing COVID-19 infection, hospitalization, ICU admission and avoiding COVID-19 related death, and COVID-19 vaccination program is cost-saving from societal perspective in China. Frontiers Media S.A. 2022-07-19 /pmc/articles/PMC9343737/ /pubmed/35928479 http://dx.doi.org/10.3389/fpubh.2022.917732 Text en Copyright © 2022 Fu, Zhao, Wei, Han, Yang, Ren, Zhan and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Fu, Yaqun Zhao, Jingyu Wei, Xia Han, Peien Yang, Li Ren, Tao Zhan, Siyan Li, Liming Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies |
title | Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies |
title_full | Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies |
title_fullStr | Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies |
title_full_unstemmed | Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies |
title_short | Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies |
title_sort | effectiveness and cost-effectiveness of inactivated vaccine to address covid-19 pandemic in china: evidence from randomized control trials and real-world studies |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343737/ https://www.ncbi.nlm.nih.gov/pubmed/35928479 http://dx.doi.org/10.3389/fpubh.2022.917732 |
work_keys_str_mv | AT fuyaqun effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies AT zhaojingyu effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies AT weixia effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies AT hanpeien effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies AT yangli effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies AT rentao effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies AT zhansiyan effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies AT liliming effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies |